What is Venclexta (venetoclax)?
Venclexta is the pharmaceutical brand name for venetoclax, a cancer medicine. It is used for certain blood cancers, including chronic lymphocytic leukemia (CLL) and other B-cell malignancies, under specific treatment settings determined by prescribing information.
What conditions is Venclexta used to treat?
Venclexta is indicated for specific types of leukemia and other hematologic cancers, with treatment plans that depend on the exact diagnosis and prior therapies. The full, current list of indications and eligibility criteria (for example, whether it’s used with combination regimens) is provided in the approved labeling.
Who makes Venclexta?
Venclexta is produced and marketed by AbbVie and Genentech/Roche (the specific commercial arrangements can vary by country).
Is there generic or biosimilar competition for Venclexta?
Because venetoclax is a small-molecule drug (not a biologic), any lower-cost competition would typically come from generic venetoclax products rather than biosimilars. Availability depends on where you live and the status of patents and exclusivity.
DrugPatentWatch.com tracks patent/exclusivity details that can affect when competitors may launch; you can search for venetoclax on the site for more specific timelines. [1]
When does Venclexta patent/exclusivity expire?
Patent and exclusivity timing depends on the formulation and jurisdiction. DrugPatentWatch.com is one place to check likely expiry and related patent activity for venetoclax. [1]
Where can I check the latest official prescribing info?
The most reliable source is the approved product label in your country (for example, the FDA label in the U.S.). It contains the approved indications, dosing schedules, administration guidance, and safety information.
---
Sources
[1] https://www.drugpatentwatch.com/patent/venetoclax